No spam - just the good stuff

Subscribe to our newsletter

News

Supplements

Combilytics: Taking a combined approach to senescence

Longevity based on research, education and transparency

A strong patent portfolio delivers a competitive edge in the longevity space

Climbing the intellectual property ladder the ChromaDex way – representatives of R&D at ChromaDex join us to talk all things patent.

Mikra announces successful study results for CELLF

SRW – changing how we experience aging at a cellular level

Longevity supplements firm eyes pet longevity

Health organisations petition FDA to reverse its position on NMN supplements

Taking vitamin D could help prevent dementia, study finds

Researchers link supplement to reduced biomarkers of Alzheimer’s in the brain

New proprietary peptide product is easy on the eye

Off the shelves: Amazon bans NMN products

Muhdo 2.0 is taking personalized longevity to a new level

Buck Institute launches first human clinical trial into ketone body supplementation

Why NMN is the supplement to watch in 2023

Interrupting the aging cascade

Improving your cardiovascular health to help maintain a healthy lifestyle

New product Insideout aims to tackle the most visible aspects of aging: skin and mobility

Hello100 launches new NMN product enriched with 5 active ingredients and liposomal tech

It’s beginning to look a lot like Krill-mas…

Spermidine – the supplement making an impact

Evidence mounts for spermidine’s potential in age-related disease

FDA says NMN cannot be sold as a dietary supplement in the US

Wonderfeel announces clinical study of its novel NMN supplement on human cells

Partnering with nature to provide Longevity as a Service

Introducing the NAD Optimization Grand Challenge

A gut feeling for improving longevity

Back to biology – Eric Verdin talks NMN and longevity supplements

‘No evidence’ that centrophenoxine provides antiaging benefits, says report

Elysium announces positive results from Basis clinical trial

ChromaDex and Nestlé announce new Niagen commercial supply agreement and $5m investment

ChromaDex shares promising findings from nicotinamide riboside clinical trial

Tackling oxidative stress by restoring, repairing and rebuilding

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.